Genfit (GNFT)

Currency in EUR
13.76
+0.30(+2.23%)
Closed·
Trading near 52-week High
GNFT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
13.4214.32
52 wk Range
3.0514.32
Key Statistics
Prev. Close
13.76
Open
13.5
Day's Range
13.42-14.32
52 wk Range
3.05-14.32
Volume
604.66K
Average Volume (3m)
319.19K
1-Year Change
325.2163%
Book Value / Share
-0.45
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GNFT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14.00
Upside
+1.74%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Genfit News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 14.00
(+1.74% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
May 22, 2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

GNFT Income Statement

Compare GNFT to Peers and Sector

Metrics to compare
GNFT
Peers
Sector
Relationship
P/E Ratio
−8.1x−2.4x−0.4x
PEG Ratio
0.00−0.050.00
Price/Book
−30.7x1.2x2.6x
Price / LTM Sales
9.8x16.5x3.0x
Upside (Analyst Target)
9.0%180.8%51.9%
Fair Value Upside
Unlock14.1%9.4%Unlock

Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase 3 clinical trial for the treatment of primary sclerosing cholangitis; GNS561, which is in Phase 1b clinical trial for the treatment of cholangiocarcinoma; and G1090N/NTZ, which is in Phase 1 clinical trial for the treatment of acute-on-chronic liver failure continuum. In addition, the company is involved in the development of drugs in preclinical stage, including SRT-015, CLM-022, and EViv for the treatment of acute-on-chronic liver failure continuum; VS-02-HE for the treatment of hepatic encephalopathy; and VS-01-HAC (UCD/OA) for the treatment of hyperammonemic crises, urea cycle disorder, and organic acidemias. It has strategic partnerships with Ipsen for the development and commercialization of elafibranor; and Labcorp for the development and commercialization of NASHnext, a blood-based molecular diagnostic test, as well as TS-01, a diagnostic tool for blood ammonia levels. The company was incorporated in 1999 and is headquartered in Loos, France.

Employees
188
Market
France

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
85.16K0.17%1.14M
Other Institutional Investors
11.76M23.62%157.65M
Public Companies & Retail Investors
37.95M76.21%508.56M
Total
49.8M100.00%667.34M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Ipsen S.A.8.00%3,985,23953,402
683 Capital Management, LLC5.91%2,942,24239,426

People Also Watch

98.34
SOIT
+0.18%
58.49
STMPA
+0.33%
8.06
ALKAL
-3.93%
32.42
AL2SI
-10.93%
33.42
NANOB
+0.97%

FAQ

What Is the Genfit (GNFT) Stock Price Today?

The Genfit stock price today is 13.76 EUR.

What Stock Exchange Does Genfit Trade On?

Genfit is listed and trades on the Paris Stock Exchange.

What Is the Stock Symbol for Genfit?

The stock symbol for Genfit is "GNFT."

What Is the Genfit Market Cap?

As of today, Genfit market cap is 688.33M EUR.

What Is Genfit's Earnings Per Share (TTM)?

The Genfit EPS (TTM) is -1.72.

When Is the Next Genfit Earnings Date?

Genfit will release its next earnings report on Sep 29, 2026.

From a Technical Analysis Perspective, Is GNFT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Genfit Stock Split?

Genfit has split 2 times.

How Many Employees Does Genfit Have?

Genfit has 188 employees.

What is the current trading status of Genfit (GNFT)?

As of Jul 09, 2026, Genfit (GNFT) is trading at a price of 13.76 EUR, with a previous close of 13.76 EUR. The stock has fluctuated within a day range of 13.42 EUR to 14.32 EUR, while its 52-week range spans from 3.05 EUR to 14.32 EUR.

What Is Genfit (GNFT) Price Target According to Analysts?

The average 12-month price target for Genfit is 14.00 EUR, with a high estimate of 15 EUR and a low estimate of 11 EUR. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +1.74% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.